Crossmark

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Crossref DOI link: https://doi.org/10.1038/s41392-024-01927-9

Published Online: 2024-08-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Hua-Qiang https://orcid.org/0000-0003-3538-4481
Zhang, Ya-Xiong https://orcid.org/0000-0002-3632-0300
Chen, Gang

Yu, Qi-Tao

Zhang, Hua

Wu, Guo-Wu

Wu, Di

Lin, Ying-Cheng

Zhu, Jun-Fei

Chen, Jian-Hua

Hu, Xiao-Hua

Lan, Bin

Zhou, Ze-Qiang

Lin, Hai-Feng

Wang, Zi-Bing

Lei, Xiao-Lin

Pan, Suo-Ming

Chen, Li-Ming

Zhang, Jian

Kong, Tian-Dong

Yao, Ji-Cheng

Zheng, Xin

Li, Feng

Zhang, Li

Fang, Wen-Feng
License Information

Text and Data Mining valid from 2024-08-13

Version of Record valid from 2024-08-13
More Information

Article History

Received: 5 February 2024

Revised: 12 June 2024

Accepted: 19 July 2024

First Online: 13 August 2024

Competing interests

: L.Z. has received research support from Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Eli Lilly, Novartis, Roche, and Bristol-Myers Squibb. Other authors declare no competing interests.

Document is current

Any future updates will be listed below